Marshall Wace
KLRS

Marshall Wace’s Kalaris Therapeutics KLRS Stock Holding History

Marshall Wace’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$567K Buy
139,201
+71,322
+105% +$370K ﹤0.01% 2462
2026
Q1 		$392K Sell
67,879
-4,997
-7% -$44.3K ﹤0.01% 2551
2025
Q4 		$615K Buy
72,876
+58,761
+416% +$376K ﹤0.01% 2158
2025
Q3 		$81.6K Hold
14,115
– – ﹤0.01% 2678
2025
Q2 		$37.7K Hold
14,115
– – ﹤0.01% 2615
2025
Q1 		$113K Sell
14,115
-1
-0% -$10 ﹤0.01% 2487
2024
Q4 		$136K Hold
14,116
– – ﹤0.01% 2410
2024
Q3 		$263K Hold
14,116
– – ﹤0.01% 2200
2024
Q2 		$234K Sell
14,116
-1,759
-11% -$31.1K ﹤0.01% 2244
2024
Q1 		$274K Buy
15,875
+1,759
+12% +$28.7K ﹤0.01% 2142
2023
Q4 		$221K Hold
14,116
– – ﹤0.01% 1956
2023
Q3 		$698K Hold
14,116
– – ﹤0.01% 1613
2023
Q2 		$1.1M Hold
14,116
– – ﹤0.01% 1673
2023
Q1 		$1.28M Hold
14,116
– – ﹤0.01% 1696
2022
Q4 		$1.67M Hold
14,116
– – ﹤0.01% 1826
2022
Q3 		$2.56M Hold
14,116
– – 0.01% 1850
2022
Q2 		$1.27M Hold
14,116
– – ﹤0.01% 2300
2022
Q1 		$2.19M Sell
14,116
-131
-0.9% -$26.1K ﹤0.01% 1994
2021
Q4 		$4.24M Buy
+14,247
New +$6.61M 0.01% 1486
2021
Q2 		– Sell
-6,650
Closed -$3.58M – 3184
2021
Q1 		$3.58M Buy
6,650
+6,292
+1,758% +$5.29M 0.02% 1020
2020
Q4 		$316K Sell
358
-694
-66% -$534K ﹤0.01% 1634
2020
Q3 		$666K Buy
+1,052
New +$718K ﹤0.01% 1158

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Marshall Wace's KLRS Position: Q2 2026 in Review

Marshall Wace increased its Kalaris Therapeutics (KLRS) stake by 105% in Q2 2026, buying an estimated $370K and bringing the position to 139,201 shares worth $567K. The position accounts for ﹤0.01% of the portfolio, ranked #2462.

Marshall Wace first reported a position in KLRS in Q3 2020 and has held it in 22 quarters since. The position peaked at $4.24M in Q4 2021. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Marshall Wace held 139,201 shares of Kalaris Therapeutics worth $567K as of Q2 2026.
  • Marshall Wace bought 71,322 Kalaris Therapeutics shares in Q2 2026, an estimated $370K.
  • Kalaris Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2462 holding.
  • Marshall Wace first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Marshall Wace's Kalaris Therapeutics position peaked at $4.24M in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.